Skip to content

IDEAYA Biosciences, Inc. IDYA Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
$2.3M+454%
Immunome logo
ImmunomeIMNM
$5.1M+199%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.59M+192%
Summit Therapeutics logo
Summit TherapeuticsSMMT
Incyte logo
IncyteINCY
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+104%

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s increase (decrease) in prepaid expense and other assets?
IDEAYA Biosciences, Inc. (IDYA) reported increase (decrease) in prepaid expense and other assets of -$3.03M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s increase (decrease) in prepaid expense and other assets changed year-over-year?
IDEAYA Biosciences, Inc.'s increase (decrease) in prepaid expense and other assets decreased by 253.6% year-over-year, from $1.97M to -$3.03M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s increase (decrease) in prepaid expense and other assets?
Over 2 years (2022 to 2025), IDEAYA Biosciences, Inc.'s increase (decrease) in prepaid expense and other assets has grown at a 94.7% compound annual growth rate (CAGR), from $2.12M to $8.03M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.